DAXOR CORPORATION — Department of Defense SBIR Phase I: A18-122
DAXOR CORPORATION — SBIR Phase I award from Department of Defense.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Defense in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $145,169. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code A18-122 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $145,169
- Agency
- Department of Defense · Army
- Program / Phase
- SBIR · Phase I
- Topic
- A18-122
- Solicitation
- 18.2
- NAICS
- —
- Place of performance
- TN
- Period
- 2018-10-15 → 2020-05-01
Description
Daxor proposes an automated, ruggedized, portable system for calculating blood, red cell, and plasma volumes, based on a comprehensive adaptation and reengineering of the current gold standard for volume measurement, the Daxor BVA-100. Significant improvements in portability (size, weight, and battery operation), logistics, speed, and ease of use are achieved. Whole blood is sampled directly from the patient, eliminating the need for centrifugation and precision pipetting. Hematocrit measurement is integrated, allowing quantification of all blood compartments. The detection system (detector and shielding) is optimized for portability, and to allow the use of a longer-life tracer. Active technician time is substantially reduced with automated blood draws, with results available in fewer than 20 minutes. Individualized patient norms are displayed along with measured values; recommended corrections to volume derangements are displayed. Achievement of required 95% accuracy is demonstrated by parallel computation using the gold-standard BVA-100, in both laboratory and hospital conditions.